DeCure for Leukoencephalopathy with vanishing white matter
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for leukoencephalopathy with vanishing white matter — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLeukoencephalopathy with vanishing white matter maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for leukoencephalopathy with vanishing white matter is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
general transcription factor IIH subunit 3 (GTF2H3) — GTF2H3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sf4drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 28JM · 3.29 Å · ligand IRON/SULFUR CLUSTER (SF4). Experimental structure, not a prediction.
What the evidence adds up to
Leukoencephalopathy with vanishing white matter is an inherited disorder with a chronic progressive course and additional episodes of rapid neurological deterioration. These episodes are typically provoked by febrile infections or minor head trauma, but a 2005 report describes two patients who experienced rapid deterioration after a fright. The condition was first thought to occur only in children, but a 2001 case report documents an adult patient presenting with dementia and extensive cerebral white matter abnormalities on MRI that met the criteria for the disease. A 2025 case report of a 39-year-old man from Palestine with adult-onset vanishing white matter disease found a homozygous pathogenic missense variant in EIF2B3 and a deletion in PRKN/PARK2. His motor symptoms were temporarily alleviated following administration of Levodopa/Carbidopa, but the authors note the long-term consequences are uncertain due to the illness's ongoing progression and the absence of a cure.
The 2025 case report describes a patient with a 7-month history of postural instability, imbalanced gait, progressive lower extremity deterioration, ocular abnormalities, and sphincteric issues. Neurological examination showed reduced cognitive function, spastic quadriparesis, hyperreflexia, bradykinesia, and shuffling gait. MRI showed periventricular white matter hyperintensities indicative of vanishing white matter leukoencephalopathy. The patient's sibling had shown comparable symptoms but died of colon cancer without a diagnosis. The authors state that adult-onset vanishing white matter accounts for 15% of cases worldwide.
The abstracts on toxic leukoencephalopathy describe a separate disorder caused by exposure to leukotoxic agents, not the inherited vanishing white matter disease. A 2004 study of treatment-induced leukoencephalopathy in primary CNS lymphoma patients found that symptoms of neurotoxicity developed a median of 1 month after treatment completion, with median survival of 30 months after neurotoxicity onset. At autopsy, myelin and axonal loss, gliosis, pallor, spongiosis, and rarefaction of the white matter were found in all five patients, and four had atherosclerosis of large cerebral vessels. The authors concluded that treatment-induced leukoencephalopathy is not a late delayed consequence but can be seen very early, and that vascular disease may be a component.
What is still missing is a cure for inherited vanishing white matter disease, with the 2025 authors explicitly stating no cure is currently known. The single case report of temporary symptom relief with Levodopa/Carbidopa in a patient who also had a PRKN/PARK2 deletion does not constitute evidence for any drug in the inherited disease itself. No controlled trials exist for any drug in vanishing white matter disease. More research is needed, particularly in regions where studies on neurological disorders are limited, and diagnostic and therapeutic capabilities require enhancement.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2004 · 177 citations
Treatment-induced leukoencephalopathy in primary CNS lymphoma
AbstractBACKGROUND: Treatment-related leukoencephalopathy is the leading toxicity after successful treatment of primary CNS lymphoma (PCNSL). Its mechanism is poorly understood and there are no autopsy data available on such patients. METHODS: From a database of immunocompetent patients with PCNSL diagnosed between 1985 and 2001, the authors identified five autopsied patients who died of leukoencephalopathy. The authors reviewed their clinical records, MRI, and autopsy findings. RESULTS: The median age was 74 years (range 41 to 79) at PCNSL diagnosis. Symptoms of neurotoxicity developed a median of 1 month after treatment completion, and median survival was 30 months (range 22 to 68 months) after neurotoxicity onset. All had white matter hyperintensity on T2-weighted MRI, and two developed enhancing lesions 5 and 14 months following completion of treatment. At autopsy no PCNSL was identified. Myelin and axonal loss, gliosis, pallor, spongiosis, and rarefaction of the white matter were found in all; two patients had tissue necrosis that correlated with the enhancement on MRI, and one had fibrinoid necrosis of vessels. Four of the five patients had atherosclerosis of large cerebral vessels in the circle of Willis and all had small vessel disease; two had recent strokes at autopsy. CONCLUSIONS: Treatment-induced leukoencephalopathy is not a late delayed consequence of neurotoxic treatment but can be seen very early in some patients. Vascular disease may be a component of this white matter injury.
Fright is a provoking factor in vanishing white matter disease
AbstractLeukoencephalopathy with vanishing white matter is an inherited disorder with a chronic progressive disease course and additional episodes of rapid neurological deterioration. These episodes typically are provoked by febrile infections or minor head trauma. We report on two patients who experienced an episode of rapid neurological deterioration after a fright.
Adult‐onset leukoencephalopathy with vanishing white matter presenting with dementia
AbstractWe report on a case of dementia and extensive cerebral white matter abnormalities seen on magnetic resonance-images which meet the criteria for leukoencephalopathy with vanishing white matter. This is an inherited condition that was first thought to occur only in children. Our patient shows that vanishing white matter should be considered in adult patients with early-onset dementia and extensive white matter changes seen on magnetic resonance images.
Journal of Neuropsychiatry · 2017 · 36 citations · open access
The Expanding Prominence of Toxic Leukoencephalopathy
AbstractToxic leukoencephalopathy (TL) is a disorder of brain white matter caused by exposure to leukotoxic agents. Magnetic resonance imaging (MRI) can readily identify this syndrome, and, together with diffusion tensor imaging, MRI continues to offer important insights into its nature. Since the first formal description of TL in 2001, many new leukotoxic disorders have been recognized, and the range of leukotoxins has expanded to include more therapeutic drugs, drugs of abuse, and environmental insults. While the understanding of pathophysiology remains incomplete, TL is increasingly common in clinical practice, and the potential long-term cognitive sequelae of toxic white matter injury merit attention.
Polish Journal of Radiology · 2017 · 27 citations · open access
Toxins in Brain! Magnetic Resonance (MR) Imaging of Toxic Leukoencephalopathy – A Pictorial Essay
AbstractToxic leukoencephalopathy results from damage to the white matter caused by various toxins. It manifests itself as white matter signal abnormalities with or without the presence of restricted diffusion. These changes are often reversible if the insulting agent is removed early, with the exception of posthypoxic leukoencephalopathy that can manifest itself 1-2 weeks after the initial insult. However, many other potential causes of white matter signal abnormalities can mimic the changes of toxic leukoencephalopathy. Thus, familiarity with the causes, clinical presentation and particularly imaging findings of toxic leukoencephalopathy is critical for early treatment and improved prognosis. The purpose of this pictorial essay is to familiarize the reader with the various causes of toxic leukoencephalopathy along with its differential diagnoses and mimics.
A rare case of adult-onset vanishing white matter leukoencephalopathy with movement disorder, expressing homozygous EIF2B3 and PRKN pathogenic variants
AbstractBACKGROUND: Vanishing white matter disease (VWMD) is a rare autosomal recessive leukoencephalopathy. It is typified by a gradual loss of white matter in the brain and spinal cord, which results in impairments in vision and hearing, cerebellar ataxia, muscular weakness, stiffness, seizures, and dysarthria cogitative decline. Many reports involve minors. Very few instances worldwide have been reported, with adult onset of vanishing white matter considered to account for 15% of cases. Clinical evaluation, MRI results, and confirmatory genetic testing are used to diagnose VWMD. CASE PRESENTATION: A 39-year-old male from Hebron, Palestine, presented with a 7-month history of postural instability, imbalanced gait, and progressive deterioration of his lower extremities. Additionally, the patient suffered from ocular abnormalities and sphincteric issues. The patient's sibling showed comparable symptoms but was never diagnosed, as he passed away because of colon cancer. Reduced cognitive function, spastic quadriparesis, hyperreflexia, bradykinesia, and shuffling gait were found during a neurological examination. Normal results were obtained from routine laboratory tests, including cerebrospinal fluid (CSF), blood, and urine. Periventricular white matter hyperintensities, which are indicative of vanishing white matter leukoencephalopathy (VWML), were identified during an MRI. The diagnosis of adult-onset VWML with movement disability was substantiated by genetic testing, which named a homozygous pathogenic missense variant, EIF2B3, and a deletion in PRKN/PARK2. The patient's motor symptoms were temporarily alleviated following the administration of Levodopa/Carbidopa. Nevertheless, the long-term consequences are uncertain due to the illness's ongoing progression and the absence of a cure currently. CONCLUSION: This instance of vanishing white matter leukoencephalopathy (VWML) is particularly remarkable in adults because of its rarity and complexity. The diagnosis is further complicated by the coexistence of Parkinsonism and VWML. Although a cure is not currently known. Early discovery is crucial to effectively manage symptoms. This example underscores the importance of more VWML research, particularly in Palestine, where studies on neurological disorders are limited. These findings underscore the importance of enhancing the region's diagnostic and therapeutic capabilities.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
